NFJ Investment Group LLC Grows Stock Holdings in Pfizer Inc. $PFE

Key Points

• NFJ Investment Group LLC increased its holdings in Pfizer Inc. by 103.6% in the 1st quarter, acquiring an additional 817,137 shares to reach a total of 1,605,974 shares.
• Pfizer reported $0.78 EPS for the latest quarter, surpassing expectations and showing a 10.3% increase in revenue from the previous year.
• The company is currently offering a dividend yield of 7.0% with a recent quarterly dividend of $0.43 per share, reflecting a payout ratio of 91.49%.

NFJ Investment Group LLC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 103.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,605,974 shares of the biopharmaceutical company's stock after buying an additional 817,137 shares during the quarter. Pfizer comprises about 1.4% of NFJ Investment Group LLC's investment portfolio, making the stock its 17th largest holding. NFJ Investment Group LLC's holdings in Pfizer were worth $40,695,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. William B. Walkup & Associates Inc. lifted its position in shares of Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co lifted its position in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after buying an additional 467 shares during the last quarter. Sutton Place Investors LLC increased its holdings in shares of Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after acquiring an additional 472 shares in the last quarter. MSH Capital Advisors LLC increased its holdings in shares of Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock valued at $876,000 after acquiring an additional 485 shares in the last quarter. Finally, Trust Asset Management LLC increased its holdings in shares of Pfizer by 0.8% during the first quarter. Trust Asset Management LLC now owns 65,183 shares of the biopharmaceutical company's stock valued at $1,652,000 after acquiring an additional 490 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.51 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company's 50 day moving average is $24.83 and its 200 day moving average is $24.36. The company has a market cap of $139.32 billion, a PE ratio of 13.03, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 EPS. The business's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Jefferies Financial Group upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America upped their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.